707 related articles for article (PubMed ID: 28463465)
21. Serotype-Independent Protection Against Invasive Pneumococcal Infections Conferred by Live Vaccine With
Jang AY; Ahn KB; Zhi Y; Ji HJ; Zhang J; Han SH; Guo H; Lim S; Song JY; Lim JH; Seo HS
Front Immunol; 2019; 10():1212. PubMed ID: 31191555
[No Abstract] [Full Text] [Related]
22. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
[TBL] [Abstract][Full Text] [Related]
23. Pneumococcal Surface Protein A does not affect the immune responses to a combined diphtheria tetanus and pertussis vaccine in mice.
Lima FA; Miyaji EN; Quintilio W; Raw I; Ho PL; Oliveira ML
Vaccine; 2013 May; 31(20):2465-70. PubMed ID: 23541622
[TBL] [Abstract][Full Text] [Related]
24. A Novel PspA Protein Vaccine Intranasal Delivered by Bacterium-Like Particles Provides Broad Protection Against Pneumococcal Pneumonia in Mice.
Wang D; Lu J; Yu J; Hou H; Leenhouts K; Van Roosmalen ML; Gu T; Jiang C; Kong W; Wu Y
Immunol Invest; 2018 May; 47(4):403-415. PubMed ID: 29498560
[TBL] [Abstract][Full Text] [Related]
25. A nontoxic adjuvant for mucosal immunity to pneumococcal surface protein A.
Yamamoto M; Briles DE; Yamamoto S; Ohmura M; Kiyono H; McGhee JR
J Immunol; 1998 Oct; 161(8):4115-21. PubMed ID: 9780183
[TBL] [Abstract][Full Text] [Related]
26. Identification of SP1683 as a pneumococcal protein that is protective against nasopharyngeal colonization.
Moens L; Hermand P; Wellens T; Wuyts G; Derua R; Waelkens E; Ysebaert C; Godfroid F; Bossuyt X
Hum Vaccin Immunother; 2018 May; 14(5):1234-1242. PubMed ID: 29400602
[TBL] [Abstract][Full Text] [Related]
27. The mucosal immune system of the upper respiratory tract and recent progress in mucosal vaccines.
Kurono Y
Auris Nasus Larynx; 2022 Feb; 49(1):1-10. PubMed ID: 34304944
[TBL] [Abstract][Full Text] [Related]
28. Nasal Flt3 ligand cDNA elicits CD11c+CD8+ dendritic cells for enhanced mucosal immunity.
Kataoka K; McGhee JR; Kobayashi R; Fujihashi K; Shizukuishi S; Fujihashi K
J Immunol; 2004 Mar; 172(6):3612-9. PubMed ID: 15004163
[TBL] [Abstract][Full Text] [Related]
29. Combined prime-boost immunization with systemic and mucosal pneumococcal vaccines based on Pneumococcal surface protein A to enhance protection against lethal pneumococcal infections.
Zhang Y; Guo X; Guo M; Chen X; Li B; Yu J; Gu T; Kong W; Wu Y
Immunol Res; 2019 Oct; 67(4-5):398-407. PubMed ID: 31773490
[TBL] [Abstract][Full Text] [Related]
30. Protection Elicited by Nasal Immunization with Recombinant Pneumococcal Surface Protein A (rPspA) Adjuvanted with Whole-Cell Pertussis Vaccine (wP) against Co-Colonization of Mice with Streptococcus pneumoniae.
Tostes RO; Rodrigues TC; da Silva JB; Schanoski AS; Oliveira ML; Miyaji EN
PLoS One; 2017; 12(1):e0170157. PubMed ID: 28103277
[TBL] [Abstract][Full Text] [Related]
31. Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge.
Campos IB; Darrieux M; Ferreira DM; Miyaji EN; Silva DA; Arêas AP; Aires KA; Leite LC; Ho PL; Oliveira ML
Microbes Infect; 2008 Apr; 10(5):481-8. PubMed ID: 18403234
[TBL] [Abstract][Full Text] [Related]
32. Increased protection against pneumococcal disease by mucosal administration of conjugate vaccine plus interleukin-12.
Lynch JM; Briles DE; Metzger DW
Infect Immun; 2003 Aug; 71(8):4780-8. PubMed ID: 12874361
[TBL] [Abstract][Full Text] [Related]
33. Characterization of the antibody response elicited by immunization with pneumococcal surface protein A (PspA) as recombinant protein or DNA vaccine and analysis of protection against an intranasal lethal challenge with Streptococcus pneumoniae.
Vadesilho CF; Ferreira DM; Moreno AT; Chavez-Olortegui C; Machado de Avila RA; Oliveira ML; Ho PL; Miyaji EN
Microb Pathog; 2012; 53(5-6):243-9. PubMed ID: 22981893
[TBL] [Abstract][Full Text] [Related]
34. Resistance of young mice to pneumococcal infection can be improved by oral vaccination with recombinant Lactococcus lactis.
Villena J; Medina M; Racedo S; Alvarez S
J Microbiol Immunol Infect; 2010 Feb; 43(1):1-10. PubMed ID: 20434117
[TBL] [Abstract][Full Text] [Related]
35. Secretory-IgA antibodies play an important role in the immunity to Streptococcus pneumoniae.
Fukuyama Y; King JD; Kataoka K; Kobayashi R; Gilbert RS; Oishi K; Hollingshead SK; Briles DE; Fujihashi K
J Immunol; 2010 Aug; 185(3):1755-62. PubMed ID: 20585031
[TBL] [Abstract][Full Text] [Related]
36. Development of lactococcal GEM-based pneumococcal vaccines.
Audouy SA; van Selm S; van Roosmalen ML; Post E; Kanninga R; Neef J; Estevão S; Nieuwenhuis EE; Adrian PV; Leenhouts K; Hermans PW
Vaccine; 2007 Mar; 25(13):2497-506. PubMed ID: 17081660
[TBL] [Abstract][Full Text] [Related]
37. Pertussis toxin improves immune responses to a combined pneumococcal antigen and leads to enhanced protection against Streptococcus pneumoniae.
Salcedo-Rivillas C; Debrie AS; Miyaji EN; Ferreira JM; Raw I; Locht C; Ho PL; Mielcarek N; Oliveira ML
Clin Vaccine Immunol; 2014 Jul; 21(7):972-81. PubMed ID: 24807055
[TBL] [Abstract][Full Text] [Related]
38. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
Miyaji EN; Dias WO; Tanizaki MM; Leite LC
FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of protective immunity responses against pneumococcal PhtD and its C-terminal in combination with outer-membrane vesicles as adjuvants.
Malekan M; Siadat SD; Aghasadeghi M; Shahrokhi N; Afrough P; Behrouzi A; Ahmadi K; Mousavi SF
J Med Microbiol; 2020 Mar; 69(3):465-477. PubMed ID: 32100705
[No Abstract] [Full Text] [Related]
40. Mucosal and systemic immune response to sublingual or intranasal immunization with phosphorylcholine.
Maseda Y; Ohori J; Tanaka N; Nagano H; Miyashita K; Kurono Y
Auris Nasus Larynx; 2018 Apr; 45(2):273-280. PubMed ID: 28478921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
